CDKN2A and cancer: Consequently, this disparity in promoter activity resulted in a loss of cancer cell specificity of ERE73 (1 + 2) MT-ARF (−13) and ERE73 (3 + 4) MT-ARF (−13) in comparison to their wild-type constructs (Figure 2D).